Manchester Spinout Imperagen Raises £5M in Seed Funding to Deploy Quantum Physics, AI Modelling and Automated Labs for Enzyme Engineering
Insider Brief Imperagen has raised £5 million in seed funding to expand its enzyme engineering platform driven by quantum physics and artificial intelligence. The funding was led by PXN Ventures, with participation from existing investors IQ Capital and Northern Gritstonebrings, bringing the company’s total capital raised to £8.5 million, according to the company. Imperagen said […]
The convergence of advanced AI, quantum computing principles, and synthetic biology is enabling new approaches to complex problems like enzyme engineering, attracting significant venture capital.
This development highlights the accelerating application of cutting-edge computational methods to synthetic biology, indicating a potential leap in capabilities for bio-manufacturing and drug discovery.
The explicit combination of quantum physics, AI modeling, and automated labs for enzyme engineering creates a more powerful and efficient synthetic biology platform for industrial and pharmaceutical applications.
- · Synthetic biology companies
- · Pharmaceutical industry
- · Chemical manufacturing
- · AI and quantum computing developers
- · Traditional enzyme engineering methods
- · Companies slow to adopt advanced computational biology
- · Biotech firms without strong AI/quantum integration
Imperagen secures substantial seed funding to expand its advanced enzyme engineering platform.
Accelerated development and commercialization of novel enzymes for various industrial and medical applications become possible.
The integration of quantum and AI in synthetic biology sets a new industry standard, leading to a broader technological arms race in bio-engineering capabilities.
This signal links to a primary source. Continuum Brief monitors and indexes it as part of the live intelligence stream — we do not republish source content.
Read at The Quantum Insider